SCM
NBIX icon

Sigma Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Sigma Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-200,000
Closed -$2.68M – 337
2013
Q2 		$2.68M Buy
+200,000
New +$2.46M 0.12% 158

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sigma Capital Management's NBIX Position: Q3 2013 in Review

Sigma Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2013, closing a stake of 200,000 shares — an estimated $2.68M sold.

Sigma Capital Management first reported a position in NBIX in Q2 2013 and held it in 1 quarter. The position peaked at $2.68M in Q2 2013. 122 funds tracked by Wall St. Rank hold NBIX as of Q3 2013.

  • Sigma Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2013 after selling out during the quarter.
  • Sigma Capital Management sold 200,000 Neurocrine Biosciences shares in Q3 2013, an estimated $2.68M.
  • Sigma Capital Management first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 1 quarter.
  • Sigma Capital Management's Neurocrine Biosciences position peaked at $2.68M in Q2 2013.
  • 122 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2013.

Based on Sigma Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.